24 May 2013
Keywords: trigen, completes, ph, study, oral, anti-coagulant, tgn
Article | 22 December 2003
UK biotechnology firm Trigen says it has successfully completed aPhase I dose-escalation study of its highly-selective oral direct
thrombin inhibitor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 December 2003
15 December 2003
23 May 2013
© 2013 thepharmaletter.com